An evaluation of known predictive biomarkers for gastric cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This review analyzes predictive biomarkers for advanced gastric cancer (GC). Identifying these biomarkers is crucial for guiding targeted therapies and improving patient prognosis in this challenging malignancy.
Area Of Science
- Oncology
- Molecular Diagnostics
- Gastroenterology
Background
- Gastric cancer (GC) is a leading cause of cancer death globally, often diagnosed at advanced stages.
- Targeted therapies are vital for advanced GC, necessitating accurate predictive biomarker assessment for treatment eligibility.
Purpose Of The Study
- To review established and emerging predictive biomarkers for gastric cancer.
- To highlight the role of these biomarkers in guiding targeted therapy selection.
Main Methods
- Comprehensive literature review of predictive biomarkers in gastric cancer.
- Analysis of current clinical practice and emerging biomarkers.
Main Results
- Established biomarkers include HER2, PD-L1, and MMR/MSI status; CLDN18.2 is a recent addition.
- Novel biomarkers under investigation include FGFR2b, EBV, MET, EGFR, and VEGF/VEGFR.
Conclusions
- Targeted therapies are transforming advanced GC treatment, but challenges like tissue heterogeneity and biomarker overlap persist.
- Interdisciplinary collaboration is essential to overcome these challenges and optimize therapeutic strategies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.